As per the collaboaration, Constellation will receive committed funding of $95m, comprising an upfront payment and research funding for a three-year collaboration period.
Constellation will also be entitled for substantial development and commercialization milestone payments, besides double-digit royalties on commercial sales of multiple products by Genentech.
Constellation is believed to retain exclusive development and commercialization rights to selected programs arising from the collaboration, for which payments would be due to Genentech upon the successful commercialization of such products.
Genentech’s option to acquire Constellation includes the BET and EZH2 programs as well as other programs outside the collaboration scope.